CMS has announced the members of the independent Coronavirus Commission on Safety and Quality in Nursing Homes, as the agency is seeking an independent review and assessment of what happened at nursing homes across the countries when COVID-19 hit.

Hospitals in the U.S. are already using dexamethasone, a commonly known steroid that’s readily available and inexpensive, to treat COVID-19 patients without waiting for confirmation of preliminary results from a British study that found the drug can greatly improve survival.

Between 40% and 45% of COVID-19 infections could be in people who display no symptoms of the illness, according to an analysis by Scripps Research published in Annals of Internal Medicine.

Why dexamethasone could be a legitimate game-changer in the fight against COVID-19—and an update on the FDA and hydroxychloroquine.

Researchers at Cleveland Clinic have created the first risk prediction model that allows healthcare providers to find the likelihood of an individual patient testing positive for COVID—19, as well as possible outcomes from the virus.

Researchers have found a link between myocardial injury and a higher risk of death among patients hospitalized in the United States for COVID-19.

A commonly known steroid drug has been found to greatly improve survival for COVID-19 patients. In fact, among severe patients, the steroid, Dexamethasone, reduced the number of deaths by one-third in a study conducted by the University of Oxford.

The FDA has revoked its emergency use authorization for hydroxychloroquine as a treatment for COVID-19 hospital patients, determining that the controversial drug was “unlikely to be effective in treating COVID-19.”